Nolte H, Fruhstorfer H, Edström H H
Institute of Anaesthesiology, Klinikum Minden, F.R.G.
Reg Anesth. 1990 May-Jun;15(3):118-24.
Ropivacaine (LEA 103) is a new long-acting local anesthetic that in animal experiments has proved to be equally potent but less toxic than bupivacaine. In this controlled double-blind study in man, the dose-response relation of ropivacaine was examined in peripheral nerve block and its potency was compared to that of bupivacaine. Nerve functions during bilateral ulnar nerve block were monitored in 70 normal subjects by a computer-controlled method. Results indicate that plain ropivacaine is optimally effective at concentrations between 0.5% and 0.75%, where it reliably blocks nerve functions for about 8 hours. Its profile of action is uniform for the different fiber groups and resembles that of bupivacaine. Addition of epinephrine does not improve latency or duration of ropivacaine nerve block. Adverse effects attributable to ropivacaine have not been observed.
罗哌卡因(LEA 103)是一种新型长效局麻药,在动物实验中已证明其效力与布比卡因相当,但毒性低于布比卡因。在这项人体对照双盲研究中,研究了罗哌卡因在周围神经阻滞中的剂量 - 反应关系,并将其效力与布比卡因进行了比较。通过计算机控制的方法对70名正常受试者双侧尺神经阻滞期间的神经功能进行了监测。结果表明,单纯罗哌卡因在浓度为0.5%至0.75%之间时效果最佳,在此浓度下它能可靠地阻断神经功能约8小时。其对不同纤维组的作用特征是一致的,与布比卡因相似。添加肾上腺素并不能改善罗哌卡因神经阻滞的潜伏期或持续时间。尚未观察到罗哌卡因引起的不良反应。